+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer



A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer



Lung Cancer 114: 96-102




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064948381

Download citation: RISBibTeXText

DOI: 10.1016/j.lungcan.2017.11.005


Related references

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer 114: 96-102, 2017

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncology Reports 37(3): 1347-1358, 2017

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review. Cancer Biology & Medicine 14(4): 418-425, 2018

Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs. Lung Cancer, 2018

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet. Oncology 16(7): 830-838, 2015

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer 96(): 87-92, 2016

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Oncologist 20(10): 1167-1174, 2016

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. Clinical Advances in Hematology & Oncology 14(1): 41, 44-5, 2016

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. Clinical Lung Cancer, 2017

Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations. Zhonghua Zhong Liu Za Zhi 39(10): 732-736, 2017

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology 11(4): 545-555, 2016

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Oncotargets and Therapy 9: 5461-5473, 2016

Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 109: 137-144, 2017

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget 8(20): 32626-32638, 2017

Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. Journal of Thoracic Oncology 9(2): 189-194, 2014